Self-Assembled Saccharide-Functionalized Amphiphilic Metallacycles As Biofilms Inhibitor Via "sweet Talking"

Guoqing Tao,Tan Ji,Ning Wang,Guang Yang,Xiaolai Lei,Wei Zheng,Rongying Liu,Xuyang Xu,Ling Yang,Guang-Qiang Yin,Xiaojuan Liao,Xiaopeng Li,Hong-ming Ding,Xiaoming Ding,Jinfu Xu,Hai-Bo Yang,Guosong Chen
DOI: https://doi.org/10.1021/acsmacrolett.9b00914
IF: 5.8
2020-01-01
ACS Macro Letters
Abstract:Bacterial biofilms are troublesome in the treatment of bacterial infectious diseases due to their inherent resistance to antibiotic therapy. Exploration of alternative antibiofilm reagents provides opportunities to achieve highly effective treatments. Herein, we propose a strategy to employ self-assembled saccharide-functionalized amphiphilic metallacycles ([2+2]-Gal, [3+3]-Gal, and [6+6]-Gal) with multiple positive charges as a different type of antibacterial reagent, marrying saccharide functionalization that interact with bacteria via "sweet talking". These self-assembled glyco-metallacycles gave various nanostructures (nanoparticles, vesicles or micron-sized vesicles) with different biofilms inhibition effect on Staphylococcus aureus (S. aureus). Especially, the peculiar self-assembly mechanism, superior antibacterial effect and biofilms inhibition distinguished the [6+6]-Gal from other metallacycles. Meanwhile, in vivo S. aureus pneumonia animal model experiments suggested that [6+6]-Gal could relieve mice pneumonia aroused by S. aureus effectively. In addition, the control study of metallacycle [3+3]-EG5 confirmed the significant role of galactoside both in the self-assembly process and the antibacterial efficacy. In view of the superior effect against bacteria, the saccharide-functionalized metallacycle could be a promising candidate as biofilms inhibitor or treatment agent for pneumonia.
What problem does this paper attempt to address?